Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Kanamycin Sulfate

FDA-approved product (capsule, oral), marketed as Kanamycin, Kanamycin Sulfate, Kantrex and 1 more.

Registered studies
50+
Lab records
73
Pathogens at ≥40%
2 of 4

Chemical structure

Chemical structure of Kanamycin Sulfate
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Bacterial disease
  • Eye infection

Indications ChEMBL records as approved, from FDA and DailyMed labels.

WHO therapeutic group
Antibiotics; Other aminoglycosides
Anti-infective classification
Classified as an existing antimicrobial.WHO ATC J01GB04; WHO ATC A07AA08; WHO ATC S01AA24

Repurposing investigation

Kanamycin Sulfate is already an antimicrobial, so it is not counted among the repurposing candidates. Its AI-predicted activity is shown below for reference.

AI-predicted activity

AI prediction · nothing measured
  • MRSA6.4% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.
  • E. coli4.8% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.
  • K. pneumoniae63.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.
  • M. tuberculosis78.3% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

  • MRSA: measured active in 1 of 11 lab records
  • E. coli: measured active in 9 of 24 lab records
  • K. pneumoniae: measured active in 4 of 11 lab records
  • M. tuberculosis: measured active in 26 of 27 lab records
Open Kanamycin Sulfate in ChEMBL Registered studies below
Show the 73 laboratory records, with sources

Loading records…

“Active” means the measured value reached this project’s laboratory cutoff (10 µM or stronger). A laboratory result does not show an effect in patients.

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

Not yet docked: queued in the docking rundetails

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

Not yet docked: queued in the docking rundetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Kanamycin Sulfate with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Comparison of Antibiotics for Pseudomonas in Early CF

    NCT00823238 · start 2004-07

    Registered record
    Registry ID
    NCT00823238
    Conditions
    Cystic Fibrosis
    Interventions
    ceftazidime and tobramycin; inhaled tobramycin
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2004-07
    Completion
    2008-05
    Enrolment
    21

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCystic Fibrosis
    Interventionceftazidime and tobramycin; inhaled tobramycin
    PhasePhase 1
    Registry statusCompleted

  • Standard vs. Biofilm Susceptibility Testing in Cystic Fibrosis (CF)

    NCT00153634 · start 2004-03

    Registered record
    Registry ID
    NCT00153634
    Conditions
    Cystic Fibrosis; Chronic Bronchitis
    Interventions
    IV amikacin; PO azithromycin; IV ceftazidime; PO ciprofloxacin; IV meropenem; IV piperacillin-tazobactam; IV ticarcillin-clavulanate; IV tobramycin
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2004-03
    Completion
    2007-11
    Enrolment
    75

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCystic Fibrosis; Chronic Bronchitis
    InterventionIV amikacin; PO azithromycin; IV ceftazidime; PO ciprofloxacin +4 more
    PhaseNot applicable
    Registry statusCompleted

  • Once-Daily Amikacin Plus Cloxacillin in Febrile Neutropenic Children

    NCT00129688 · start 2002-04

    Registered record
    Registry ID
    NCT00129688
    Conditions
    Neutropenia; Cancer; Fever
    Interventions
    cloxacillin and amikacin (once or twice daily dosage)
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2002-04
    Completion
    2004-06
    Enrolment
    166

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionNeutropenia; Cancer; Fever
    Interventioncloxacillin and amikacin (once or twice daily dosage)
    PhaseNot applicable
    Registry statusCompleted

  • UARK 98-026 TT II: Multiple Myeloma Evaluating Anti-Angiogenesis With Thalidomide and Post-Transplant Consolidation Chemotherapy

    NCT00083551 · start 1998-08

    Registered record
    Registry ID
    NCT00083551
    Conditions
    Multiple Myeloma
    Interventions
    Thalidomide; Ara-C; BCNU; Cisplatin; Cytoxan; Dexamethasone; Doxorubicin; Etoposide; Filgrastim; Recombinant GM-CSF; Interferon-alpha-2b; Melphalan; Vincristine
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    1998-08
    Completion
    2014-08
    Enrolment
    668

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMultiple Myeloma
    InterventionThalidomide; Ara-C; BCNU; Cisplatin +9 more
    PhasePhase 3
    Registry statusCompleted

  • Phase III Randomized Study of the Inhalation of Tobramycin in Patients With Cystic Fibrosis

    NCT00004829 · start 1995-06

    Registered record
    Registry ID
    NCT00004829
    Conditions
    Cystic Fibrosis; Bacterial Infection
    Interventions
    tobramycin
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    1995-06
    Completion
    1998-05
    Enrolment
    200

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCystic Fibrosis; Bacterial Infection
    Interventiontobramycin
    PhasePhase 3
    Registry statusCompleted